Besides cetuximab and other monoclonal antibodies (mAbs) targeting EGFR in HNSCC patients, immunotherapy in the treatment of HNSCC has been recognized as a potential approach for improvement of clinical outcomes in patients [92]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.